MedTrace Logo

Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV)

NCT07560059 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2026-04-30

No results posted yet for this study

Summary

Diabetes is a major risk factor for severe COVID-19 and poor clinical outcomes during hospitalization. However, little is known about the medium- and long-term metabolic consequences of COVID-19 in people with diabetes after hospital discharge.

The DMD-COV study is a prospective, multicenter observational cohort conducted in Algeria. Its aim is to evaluate the cardio-metabolic outcomes of adult patients with diabetes who were hospitalized for confirmed COVID-19 and survived the acute phase of the infection.

Adult patients with type 1 or type 2 diabetes will be included during hospitalization or within 30 days after hospital discharge. Participants will be followed for up to one year after discharge, with scheduled evaluations at baseline, 3 months, 6 months, and 12 months.

During follow-up, clinical, biological, and therapeutic data will be collected, including glycemic control (HbA1c), body weight, lipid profile, kidney function, and diabetes treatments. The main outcome is the proportion of patients achieving their individualized HbA1c target at 6 months and 12 months after hospitalization for COVID-19.

The results of this study will help to better understand the long-term metabolic impact of COVID-19 in people with diabetes and to improve post-COVID diabetes management.

Conditions

Interventions

OTHER

No intervention (observational study)

This is a non-interventional observational study. No experimental or therapeutic intervention is assigned as part of the study protocol. All medical care and treatments are provided according to routine clinical practice.

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Algerian Society of Internal Medicine

    collaborator OTHER

  • Algerian Society of Diabetology

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2022-08-24
Completion
2022-08-24

Countries

  • Algeria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07560059 on ClinicalTrials.gov